Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Usha Krishnan has a total of 429 co-authors. Here are the top co-authors by number of shared publications:

  • Erika Berman Rosenzweig

    Departments of Pediatrics Maria Fareri Children's Hospital of Westchester Medical Center Health Network and New York Medical College Valhalla New York USA

    11 shared publications
  • Steven T. Leach

    Discipline of Pediatrics, School of Clinical Medicine, Faculty of Medicine and Health University of New South Wales Sydney New South Wales Australia

    5 shared publications
  • Mary P. Mullen

    Department of Cardiology Boston Children's Hospital Boston Massachusetts USA

    4 shared publications
  • Emile A. Bacha

    Division of Cardiac, Thoracic, and Vascular Surgery, New York Presbyterian-Morgan Stanley Children's Hospital, Columbia University Irving Medical Center, New York, NY, USA

    3 shared publications
  • Eric D. Austin

    Pulmonary Medicine Vanderbilt University and Vanderbilt University Medical Center Nashville Tennessee USA

    3 shared publications
  • Erika B. Rosenzweig

    Division of Pediatric Cardiology, Department of Pediatrics, Columbia University Irving Medical Center–New York Presbyterian Hospital, New York, New York

    3 shared publications

Latest Publications

  • Open Access

    Antithrombotic Therapy Use in Children With Pulmonary Hypertension

    by Meredith J. O'NEil, Lynn A. Sleeper, Nidhy P. Varghese, Paul J. Critser, Eric D. Austin, Catherine M. Avitabile, Angela Bates, Erika B. Rosenzweig, Carly E. Byrd, Patrick D. Evers, et al.

    The role of antithrombotic therapy in pulmonary hypertension (PH) remains uncertain, with conflicting adult data and limited pediatric evidence. This study aimed to describe real‐world antithrombotic use in pediatric PH utilizing Pediatric Pulmonary Hypertension Network (PPHNet) registry data and a survey of PPHNet centers. We analyzed data of 1,716 patients from the PPHNet registry (2014–2024), comparing characteristics of those who received aspirin or warfarin with those who did not. A survey on real‐world antithrombotic use was also distributed to 12 North American PPHNet centers in 2023. Eighteen percent of subjects received aspirin and 7% received warfarin. Patients who received aspirin or warfarin were more likely to have idiopathic/heritable PH. Aspirin or warfarin‐treated patients demonstrated higher‐risk features as evidenced by use of PH‐targeted triple therapy (aspirin vs. no aspirin: 22% vs. 9%, p < 0.01; warfarin vs. no warfarin: 31% vs. 10%; p < 0.01) and higher mortality over a median follow‐up of 3.2 years (aspirin vs. no aspirin: 14% vs. 9%, p = 0.008; warfarin vs. no warfarin: 19% vs. 9%, p = 0.001). Center‐specific aspirin and warfarin use varied widely. Survey data demonstrated general agreement that antithrombotic therapy was not indicated for patients at lowest risk and probably indicated for patients at highest risk, but management of intermediate‐risk patients varied considerably. Antithrombotic therapy is used infrequently in pediatric PH and primarily reserved for high‐risk patients, with significant variation across centers. These findings highlight the need for further research to define which patients may benefit and guide evidence‐based practice.

  • Neonatal Pulmonary Hypertension: Integrating Developmental, Inflammatory, Gut, Fetomaternal, and Cardio‐Pulmonary Biology Into Bedside Care

    by Bibhuti B. Das, Usha S. Krishnan

    Neonatal pulmonary hypertension (NPH) is best understood as a dynamic multisystem syndrome rather than an isolated pulmonary vascular disorder. Disruption of postnatal pulmonary vascular transition occurs within a broader biological network that includes developmental lung‐vascular biology, placental and fetomaternal influences, infection and inflammation, myocardial adaptation, and emerging gut‐lung‐vascular signaling pathways. This narrative review summarizes current evidence and expert consensus to reframe NPH across the spectrum of acute maladaptation, developmental lung disease and underdevelopment phenotypes, and prematurity‐associated mixed physiology encountered in the neonatal intensive care unit, including infants who remain hospitalized beyond 28 days of life. Pulmonary arterial pressure in the newborn reflects the interaction of pulmonary vascular resistance, pulmonary blood flow, and left atrial pressure. Targeted neonatal echocardiography is essential for phenotype recognition, real‐time hemodynamic assessment, and treatment selection. Developmental lung biology, genetic susceptibility, prenatal programming, inflammatory injury, and emerging gut‐lung interactions converge to produce pulmonary vascular dysfunction, abnormal pulmonary vascular adaptation, and right ventricular pressure overload. Understanding these interacting systems supports physiology‐guided bedside care that integrates respiratory, cardiovascular, and systemic management strategies. Management should therefore move beyond reflex vasodilation toward individualized respiratory support, physiology‐guided hemodynamic optimization, selective use of pulmonary vasodilators, and longitudinal surveillance of the developing heart‐lung unit.


  • Eosinophilic gastrointestinal diseases

    by Marco Vincenzo Lenti, Carlo Maria Rossi, Evan S. Dellon, Alfredo J. Lucendo, Akinari Sawada, Antonella Cianferoni, Usha Krishnan, Margaret H. Collins, Edoardo Vincenzo Savarino, Antonio Di Sabatino


  • Open Access

    Alternative Therapeutic Approaches in the Management of Gastroparesis: A Systematic Review

    by Desaree Tan, Serena Singh, Usha Krishnan, Vincent Ho

    Background: Gastroparesis is characterised by prolonged gastric emptying in the absence of mechanical gastric obstruction. When symptomatic, gastroparesis significantly impacts quality of life. While current consensus emphasises medical, surgical, or nutritional therapies, data evaluating the efficacy of alternative therapies remains scarce. Here, we review the efficacy of alternative therapies; acupuncture, electroacupuncture, moxibustion, and herbal medicine as management strategies. Methods: A systematic literature review of the literature was performed until February 2025. All papers were published from 2001 to 2024. This search focusses on the efficacy of acupuncture, electroacupuncture, moxibustion, and herbal medicines for management of gastroparesis. A comprehensive search was performed in PubMed, Embase, Medline, Google Scholar, Science Direct, and Web of Science. There were no language restrictions. Study outcomes were compared in a narrative synthesis and quality was assessed using Critical Appraisal Skills Programme (CASP) checklists. Results: We identified 68 studies of acupuncture, electroacupuncture, moxibustion, and herbal medicine as alternate therapies for gastroparesis. The total patient sample size of included studies was 4566, with a mean sample of 70.25 per study. The focus of studies comprising our review was electroacupuncture (11%), moxibustion (11%), acupuncture (29%), and herbal medicine (49%). Control comparisons were made with Mosapride, Metoclopramide, Domperidone, and Itopride. Conclusions: We found that alternative therapies are effective for the management of gastroparesis. However, the review was limited by heterogeneous study designs, incomplete methodological reporting, and publication bias. Future investigations must focus on long-term randomised control trials encompassing large sample sizes.

  • Interorgan Communication—Pulmonary Vein Stenosis in Children—A Review of Epidemiology, Pathophysiology, and Current Management Principles

    by Usha S. Krishnan, Mary P. Mullen

    Understanding communication between various organ systems is vital to understanding the pathophysiology of disease, and this assists in tailoring appropriate therapies. Pulmonary vein stenosis is an example of a multi‐organ disease process that occurs in infancy and later throughout life. The organs involved may be at a distance from the heart and lungs or from within the thoracic cavity. In former preterm infants with bronchopulmonary dysplasia (BPD), this condition is associated with ongoing inflammation in other organ systems, including lung parenchyma as well as the gut. It is also associated with perturbation in blood flow due to intracardiac shunt lesions or external pressure from intrathoracic structures. In patients with congenital heart disease (CHD) associated with PVS at baseline or after surgery involving pulmonary veins, there may be a genetic component to the development of PVS as well as factors like flow and shear stress and other less understood instigators of tissue proliferation within the veins. Understanding these interactions has led to improved surveillance as well as the development of protocols for the evaluation of pulmonary veins in the setting of infection or inflammation of the other organs and in patients otherwise predisposed to developing PVS. This early surveillance has resulted in prompt diagnosis, targeted drug development tailored to the disease process, appropriate and timely intervention with improved outcomes.

  • Evaluation of timing of repair of congenital diaphragmatic hernia in premature infants

    by Yeu Sanz Wu, Alysala Malik, Ashley H. Ebanks, Darina Kirilina, Paul Kurlansky, Usha S. Krishnan, Vincent P. Duron

  • Open Access

    Enhancing Drug Development for Paediatric Pulmonary Hypertension—An Integrative Perspective

    by Steven H. Abman, Sylvia M. Nikkho, Rolf M. F. Berger, Maria Jesus del Cerro, Eric D. Austin, Maurice Beghetti, Dunbar Ivy, Megan Griffiths, Anne Hilgendorff, Steven H. Kawut, et al.

    As with adult pulmonary hypertension (PH), high morbidity and mortality persist with diverse types of paediatric PH. Despite major advances in pharmacologic therapies based on extensive studies in adult PH, few drugs have been comprehensively studied in neonates, infants, and children, leaving current paediatric PH care largely dependent on small observational studies and extrapolation of evidence from adult clinical trials. Challenges in developing successful clinical trials in children include the need to define distinct disease phenotypes with well‐characterised natural history and outcomes, the lack of established age‐ and disease‐specific study endpoints, small and heterogeneous paediatric populations, and the common off‐label use of PH‐targeted drug therapies without regulatory approval. From a regulatory perspective, sufficient studies of safety, pharmacokinetics, and pharmacodynamics in neonates and young children are often lacking, and the potential role for bridging biomarkers has been underexplored. Additional opportunities include developing innovative trial designs, employing real‐world data from existing registries, and fostering collaborations among sponsors, regulatory authorities, physicians, patients, and their families. By reducing reliance on off‐label drug use and leveraging paediatric PH registry data, this approach offers a path toward more effective and evidence‐based treatment protocols for paediatric patients. This review provides an overview of integrated international perspectives from an interprofessional platform that includes academia, the pharmaceutical industry, and regulatory agencies surrounding the future design of clinical trials for paediatric PH. Ongoing evaluation and adaptation of these strategies will be essential for ensuring that paediatric PH patients receive the highest standard of care.


  • Initial Survival and Short-term Pulmonary Comorbidities in Infants With Congenital Diaphragmatic Hernia of Differing Indices of Social Determinants of Health

    by Yeu Sanz Wu, Alysala Malik, Chunhui Wang, Christian Welch, Caitlin J. Cain-Trivette, Christopher Nemeh, Nicholas Schmoke, Paul Kurlansky, Usha S. Krishnan, Aliva De, et al.


  • Open Access

    Clinical yield of esophagogastroduodenoscopy and pH-impedance testing in esophageal atresia patients performed according to international guidelines

    by M van Lennep, C Mussies, M A Benninga, R R Gorter, U Krishnan, M P van Wijk

    Summary: : According to the European Society for Paediatric Gastroenterology Hepatology And Nutrition & North American Society For Pediatric Gastroenterology, Hepatology And Nutrition (ESPGHAN-NASPGHAN) guideline, esophageal atresia (EA) patients should routinely undergo esophagogastroduodenoscopy (EGD) with biopsies and/or pH-impedance (pH multichannel intraluminal impedance test; pH-MII) for surveillance purposes. It is additionally recommended to perform these procedures when there is a clinical indication: symptoms suggestive of gastroesophageal reflux disease or eosinophilic esophagitis. The aim of this study was to evaluate how often EGD/pH-MII outcomes change management decisions in EA children who come for surveillance and/or for clinical evaluation of their symptoms. A retrospective chart review was conducted of all EA patients who received EGD and/or pH-MII for routine surveillance or because of clinical indication, i.e. symptoms suggestive of gastroesophageal reflux disease or eosinophilic esophagitis. For each procedure, we assessed whether outcomes changed management decisions. Between 2017 and 2020, 41 patients (median age 2.0 [1.0–17.5] years) underwent EGD/pH-MII for surveillance purposes and 64 (3.0 [0.1–15.8] years) for symptom evaluation. Of the 41 patients who underwent surveillance EGD/pH-MII, 18 (43.9%) were asymptomatic when interviewed. Eight of these 18 (44.4%) had results that changed management decisions. In total, 23/41 (56.1%) had results that changed management decisions. Sixty-four patients presented clinically with (a combination of) dysphagia (n = 50; 78.1%), regurgitation (n = 37; 57.8%), heartburn (n = 18; 28.1%), and/or respiratory symptoms that were thought to have a gastrointestinal origin (n = 24; 37.5%). Results changed management decisions in 34/64 (53.1%) patients who presented with symptoms. There is a high clinical yield of EGD and pH-MII testing in EA patients. More than half of the patients, regardless of indication (routine surveillance or symptom evaluation), had EGD and/or pH-MII results that changed management decisions. What is known: What is new:


  • Reply to “Proton pump inhibitors and esophageal atresia: Too early to change clinical practice”

    by Usha Krishnan, Tiffany C. Tang, Michael J. Coffey, Steven T. Leach